PDL1 positive NK cell cancer therapy

Provided herein are methods of treating cancer in a subject comprising detecting the amount of PD-L1 (+) natural killer (NK) cells in a biological sample from the subject, and treating the subject with an anti-cancer therapy. Provided herein are methods of treating cancer in a patient comprising iso...

Full description

Saved in:
Bibliographic Details
Main Authors YU JIANHUA, DONG WENJUAN, CALIGIURI MICHAEL A
Format Patent
LanguageChinese
English
Published 11.03.2022
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Provided herein are methods of treating cancer in a subject comprising detecting the amount of PD-L1 (+) natural killer (NK) cells in a biological sample from the subject, and treating the subject with an anti-cancer therapy. Provided herein are methods of treating cancer in a patient comprising isolating natural killer (NK) cells from a subject, generating a population of PD-L1 (+) NK cells from the isolated NK cells, and administering the population of PD-L1 (+) NK cells to the patient. 本文提供了治疗受试者的癌症的方法,所述方法包括检测来自所述受试者的生物样本中PD-L1(+)自然杀伤(NK)细胞的量,以及用抗癌疗法治疗所述受试者。本文提供了治疗患者的癌症的方法,所述方法包括从受试者中分离出自然杀伤(NK)细胞,从所述分离的NK细胞中产生PD-L1(+)NK细胞群,以及将所述PD-L1(+)NK细胞群施用给所述患者。
AbstractList Provided herein are methods of treating cancer in a subject comprising detecting the amount of PD-L1 (+) natural killer (NK) cells in a biological sample from the subject, and treating the subject with an anti-cancer therapy. Provided herein are methods of treating cancer in a patient comprising isolating natural killer (NK) cells from a subject, generating a population of PD-L1 (+) NK cells from the isolated NK cells, and administering the population of PD-L1 (+) NK cells to the patient. 本文提供了治疗受试者的癌症的方法,所述方法包括检测来自所述受试者的生物样本中PD-L1(+)自然杀伤(NK)细胞的量,以及用抗癌疗法治疗所述受试者。本文提供了治疗患者的癌症的方法,所述方法包括从受试者中分离出自然杀伤(NK)细胞,从所述分离的NK细胞中产生PD-L1(+)NK细胞群,以及将所述PD-L1(+)NK细胞群施用给所述患者。
Author DONG WENJUAN
YU JIANHUA
CALIGIURI MICHAEL A
Author_xml – fullname: YU JIANHUA
– fullname: DONG WENJUAN
– fullname: CALIGIURI MICHAEL A
BookMark eNrjYmDJy89L5WRQCXDxMVQoyC_OLMksS1Xw81ZITs3JUUhOzEtOLVIoyUgtSiyo5GFgTUvMKU7lhdLcDIpuriHOHrqpBfnxqcUFicmpeakl8c5-hoYmhubG5pYmjsbEqAEAgaYnmQ
ContentType Patent
DBID EVB
DatabaseName esp@cenet
DatabaseTitleList
Database_xml – sequence: 1
  dbid: EVB
  name: esp@cenet
  url: http://worldwide.espacenet.com/singleLineSearch?locale=en_EP
  sourceTypes: Open Access Repository
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Chemistry
Sciences
DocumentTitleAlternate PDL1阳性NK细胞癌症治疗
ExternalDocumentID CN114173794A
GroupedDBID EVB
ID FETCH-epo_espacenet_CN114173794A3
IEDL.DBID EVB
IngestDate Fri Aug 30 05:41:00 EDT 2024
IsOpenAccess true
IsPeerReviewed false
IsScholarly false
Language Chinese
English
LinkModel DirectLink
MergedId FETCHMERGED-epo_espacenet_CN114173794A3
Notes Application Number: CN202080046676
OpenAccessLink https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20220311&DB=EPODOC&CC=CN&NR=114173794A
ParticipantIDs epo_espacenet_CN114173794A
PublicationCentury 2000
PublicationDate 20220311
PublicationDateYYYYMMDD 2022-03-11
PublicationDate_xml – month: 03
  year: 2022
  text: 20220311
  day: 11
PublicationDecade 2020
PublicationYear 2022
RelatedCompanies WEIGHTING CITY
RelatedCompanies_xml – name: WEIGHTING CITY
Score 3.5180101
Snippet Provided herein are methods of treating cancer in a subject comprising detecting the amount of PD-L1 (+) natural killer (NK) cells in a biological sample from...
SourceID epo
SourceType Open Access Repository
SubjectTerms CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Title PDL1 positive NK cell cancer therapy
URI https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20220311&DB=EPODOC&locale=&CC=CN&NR=114173794A
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwY2BQAZ14aZpilKibkpSSqmtiZG6pm5RibKxrkmxpamGRDLo3Dbzaws_MI9TEK8I0gokhC7YXBnxOaDn4cERgjkoG5vcScHldgBjEcgGvrSzWT8oECuXbu4XYuqhBe8dGRsA0aqjm4mTrGuDv4u-s5uxs6-yn5hdkC2z2G5obAxOfIzMDK6gZDTpn3zXMCbQrpQC5SnETZGALAJqWVyLEwFSVIczA6Qy7eU2YgcMXOuENZELzXrEIg0qAi4-hAmSRVVmqgp-3AmjQXSEZFG1FCpB9VJWiDIpuriHOHrpA6-Lhfot39kO4zFiMgQXY50-VYFAwS01KMbBMTExKMTMzSUy0TExOMTNIMzFLAbb_DVMskyUZpHCbI4VPUpqBCxROoGVUhoYyDCwlRaWpssB6tSRJDhwgALw0ewo
link.rule.ids 230,309,786,891,25594,76906
linkProvider European Patent Office
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfR3LTsMwzBoDMW4wQDBeRZp6q1j6XA8VYumqwrqsQgXtNrVNEXCAaSsg-HqcrGNc4BYlkpM4dvyI7QC0RcVLi-upxjNeaKbuuFrGDUMzc9fqdnPxb5qMtmB2eGfejK1xDZ6XuTCyTuiHLI6IHJUjv5fyvp6unFi-jK2cX2RP2PV6GSSer1bWsa4jjRLV73n9eOSPqEqpR5nKbj1U-4ljIPFdrcG6I6rzCtXpvieyUqa_RUqwDRsxQnspd6D29diEBl3-vNaEzWH14I3Nivfmu9CO_YgoiyCr90JhA0U43ZVcHNtMWeRRfe7BedBPaKjhdJOfvU0oW63M2Ic62vzFASh2kfGOm6YZt20zTd0053bnwbQ56v-Eu_khtP6G0_pv8AwaYTKMJtE1GxzBlsCZCKki5Bjq5eytOEEZW2anEjnfpYp99w
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&rft.title=PDL1+positive+NK+cell+cancer+therapy&rft.inventor=YU+JIANHUA&rft.inventor=DONG+WENJUAN&rft.inventor=CALIGIURI+MICHAEL+A&rft.date=2022-03-11&rft.externalDBID=A&rft.externalDocID=CN114173794A